米索前列醇治疗与期待管理在早期非存活妊娠伴阴道出血女性中的比较:一项实用性随机对照试验
在瑞典Skåne大学医院开展的平行随机对照开放标签试验中,94例早期非存活妊娠伴阴道出血患者接受阴道米索前列醇800μg单次治疗,95例接受期待管理。随机化后10天内完全流产率米索前列醇组为66%(62/94),期待管理组为43%(39/90),风险差23%(95%CI 8-37%);两组均无严重副作用,但米索前列醇组疼痛更常见。
要点
- 超声评估完全排空标准为宫腔内无妊娠囊且宫腔内内容物最大前后径<15mm(经阴道超声正中矢状面测量)。
- 米索前列醇组10天内完全流产率66%(62/94),期待管理组43%(39/90),风险差23%(95%CI 8-37%)。
- 米索前列醇组疼痛发生率100%(91/91)高于期待管理组92%(71/77),使用止痛药比例93%(85/91)高于77%(59/77)。
核心结论
- 在早期非存活妊娠伴阴道出血女性中,米索前列醇治疗在完全排空子宫方面比期待管理更有效;两种方法均安全,但米索前列醇治疗与更多疼痛相关。
研究设计与样本
- 实用性平行随机对照开放标签试验,在瑞典Skåne大学医院开展;纳入无胚胎妊娠或早期胎儿 demise(头臀长≤33mm)伴阴道出血患者,随机分配至期待管理组或阴道单次800μg米索前列醇治疗组;意向性分析;主要结局为随机化后10天内无D&E的完全流产。
诊断标准与关键数值
- 完全排空子宫的超声标准为经阴道超声正中矢状面显示宫腔内无妊娠囊且宫腔内内容物最大前后径<15mm;随访计划在10、17、24和31天;若31天内流产未完全则推荐D&E。
临床应用与阅片要点
- 超声随访采用经阴道超声正中矢状面测量宫腔内内容物最大前后径,以<15mm且无妊娠囊作为完全排空的判定标准;米索前列醇组10天内完全流产率66%(62/94) vs 期待管理组43%(39/90),风险差23%(95%CI 8-37%);31天时分别为86%(81/94) vs 61%(55/90),风险差25%(95%CI 12-38%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To compare vaginal misoprostol treatment with expectant management in early non-viable pregnancy with vaginal bleeding with regard to complete evacuation of the uterine cavity within 10 days after randomization.
METHODS: This was a parallel randomized controlled, open-label trial conducted in Skåne University Hospital, Sweden. Patients with anembryonic pregnancy or early fetal demise (crown-rump length ≤ 33 mm) and vaginal bleeding were randomly allocated to either expectant management or treatment with a single dose of 800 μg misoprostol administered vaginally. Patients were evaluated clinically and by ultrasound until complete evacuation of the uterus was achieved (no gestational sac in the uterine cavity and maximum anteroposterior diameter of the intracavitary contents < 15 mm as measured by transvaginal ultrasound on midsagittal view). Follow-up visits were planned at 10, 17, 24 and 31 days. Dilatation and evacuation (D&E) was recommended if miscarriage was not complete within 31 days, but was performed earlier at patient's request, or if there was excessive bleeding as judged clinically. Analysis was by intention to treat. The main outcome measure was number of patients with complete miscarriage without D&E ≤ 10 days.
RESULTS: Ninety-four patients were randomized to misoprostol treatment and 95 to expectant management. After exclusion of three patients and withdrawal of consent by two patients in the expectant management group, 90 women were included in this group. Miscarriage was complete ≤ 10 days in 62/94 (66%) of the patients in the misoprostol group and in 39/90 (43%) of those in the group managed expectantly (risk difference (RD) = 23%; 95% CI, 8-37%). At 31 days, the corresponding figures were 81/94 (86%) and 55/90 (61%) (RD = 25%; 95% CI, 12-38%). Two patients from each group underwent emergency D&E because of excessive bleeding and one of these in each group received blood transfusion. The number of patients undergoing D&E at their own request was higher in the expectantly managed group, 15/90 (17%) vs 3/94 (3%) in the misoprostol group (RD = 14%; 95% CI, 4-23%), as was the number of patients making out-of-protocol visits, 50/90 (56%) vs 27/94 (29%) (RD = 27%; 95% CI, 12-40%). Compared with the expectant management group, more patients in the misoprostol group experienced pain (71/77 (92%) vs 91/91 (100%); RD = 8%; 95% CI, 1-17%) and used painkillers (59/77 (77%) vs 85/91 (93%); RD = 17%; 95% CI, 5-29%). No major side effect was reported in any group.
CONCLUSIONS: In women with early non-viable pregnancy and vaginal bleeding, misoprostol treatment is more effective than is expectant management for complete evacuation of the uterus. Both methods are safe but misoprostol treatment is associated with more pain than is expectant management. Copyright © 2017 ISUOG. Published by John Wiley & Sons Ltd.
引用
- Fernlund A, Jokubkiene L, Sladkevicius P, et al. Misoprostol treatment vs expectant management in women with early non-viable pregnancy and vaginal bleeding: a pragmatic randomized controlled trial. Ultrasound Obstet Gynecol. 2017. PMID: 29072372. doi:10.1002/uog.18940
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。